Literature DB >> 16226443

Identifying 'well-controlled' and 'not well-controlled' asthma using the Asthma Control Questionnaire.

Elizabeth F Juniper1, Jean Bousquet, Linda Abetz, Eric D Bateman.   

Abstract

The 7-item Asthma Control Questionnaire (ACQ) has been validated to measure the goals of asthma management as defined by international guidelines (minimisation of day- and night-time symptoms, activity limitation, beta(2)-agonist use and bronchoconstriction). Responses are given on a 7-point scale and the overall score is the mean of the responses (0=totally controlled, 6=severely uncontrolled). The aim of this analysis was to determine the cut-point on the ACQ that best differentiates between 'well-controlled' and 'not well-controlled' for (a) clinical practice (low risk of missing 'not well-controlled') and (b) clinical trials (low risk of including 'well-controlled'). All 1323 patients who provided data sets at week 12 in the Gaining Optimal Asthma Control (GOAL) clinical trial were included in the analysis. The gold standard for 'well-controlled' was a composite based on the GINA/NIH guidelines and derived from data collected in the clinical trial diaries and clinic records. The analysis showed that the crossover point between 'well-controlled' and 'not well-controlled' is close to 1.00 on the ACQ. However, to be confident that a patient has well-controlled asthma, the optimal cut-point is 0.75 (negative predictive value=0.85). To be confident that the patient has inadequately controlled asthma, the optimal cut-point is 1.50 (positive predictive value=0.88). In conclusion, knowledge of these cut-points will enhance practising clinicians ability to identify patients whose asthma requires additional treatment, enable investigators to enroll poorly controlled patients into studies and for both clinicians and investigators to evaluate whether treatment goals are being achieved.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16226443     DOI: 10.1016/j.rmed.2005.08.012

Source DB:  PubMed          Journal:  Respir Med        ISSN: 0954-6111            Impact factor:   3.415


  224 in total

1.  Feasibility and acceptability of using bronchial hyperresponsiveness to manage asthma in primary care: a pilot study.

Authors:  James A Turton; Nicholas J Glasgow; John D Brannan
Journal:  Prim Care Respir J       Date:  2012-03

Review 2.  Drug development for severe asthma: what are the metrics?

Authors:  Cynthia B Robinson; Joanne Leonard; Reynold A Panettieri
Journal:  Pharmacol Ther       Date:  2012-05-22       Impact factor: 12.310

3.  Characterization of a high TNF-α phenotype in children with moderate-to-severe asthma.

Authors:  Sheena D Brown; Lou Ann Brown; Susan Stephenson; Jennifer C Dodds; Shaneka L Douglas; Hongyan Qu; Anne M Fitzpatrick
Journal:  J Allergy Clin Immunol       Date:  2015-02-26       Impact factor: 10.793

4.  Associations of Fraction of Exhaled Nitric Oxide with Beta Agonist Use in Children with Asthma.

Authors:  Adam J Spanier; Robert S Kahn; Richard Hornung; Michelle Lierl; Bruce P Lanphear
Journal:  Pediatr Allergy Immunol Pulmonol       Date:  2011-03       Impact factor: 1.349

5.  Using the pediatric asthma therapy assessment questionnaire to measure asthma control and healthcare utilization in children.

Authors:  Gregory B Diette; Shiva G Sajjan; Elizabeth A Skinner; Thomas W Weiss; Albert W Wu; Leona E Markson
Journal:  Patient       Date:  2009-12-01       Impact factor: 3.883

6.  Reference range number line format preferred by adults for display of asthma control status.

Authors:  Adriana Arcia; Maureen George
Journal:  J Asthma       Date:  2019-04-03       Impact factor: 2.515

7.  Methacholine PC20 in African Americans and whites with asthma with homozygous genotypes at ADRB2 codon 16.

Authors:  Kathryn Blake; James D Cury; Jobayer Hossain; Kelan Tantisira; Jianwei Wang; Edward Mougey; John Lima
Journal:  Pulm Pharmacol Ther       Date:  2013-02-04       Impact factor: 3.410

8.  Systemic Corticosteroid Responses in Children with Severe Asthma: Phenotypic and Endotypic Features.

Authors:  Anne M Fitzpatrick; Susan T Stephenson; Milton R Brown; Khristopher Nguyen; Shaneka Douglas; Lou Ann S Brown
Journal:  J Allergy Clin Immunol Pract       Date:  2016-09-21

9.  A 12-week, Randomized, Parallel-group, Phase III Study Comparing the Efficacy of Once-daily Budesonide/formoterol Turbuhaler (160/4.5 μg/d) with Twice-daily Budesonide (400 μg/d) During the Step-down Period in Well-controlled Asthma.

Authors:  Narongwit Nakwan; Thitima Perkleang; Thanida Tamsawai; Pattarawadee Taptawee; Sirikade Usaha
Journal:  Turk Thorac J       Date:  2018-04-01

10.  Behavioral weight loss and physical activity intervention in obese adults with asthma. A randomized trial.

Authors:  Jun Ma; Peg Strub; Lan Xiao; Philip W Lavori; Carlos A Camargo; Sandra R Wilson; Christopher D Gardner; A Sonia Buist; William L Haskell; Nan Lv
Journal:  Ann Am Thorac Soc       Date:  2015-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.